

S&K Therapeutics

Ajou University Campus Plaza 418, Worldcup-ro 199, Yeongtong-gu, Suwon-si, Gyeonggi-do, 16502, Korea
Email: sangdunchoi@ajou.ac.kr

Biography

S&K Therapeutics is a biopharmaceutical company founded in July 2020. S&K develops an innovative therapeutic approach based upon first-in-class inhibitors (small molecules) that modulate drug targets such as TLRs, TNF α , NLRP3, IL23, IL17, and IL18. We employ cutting-edge science and technology (artificial intelligence, machine learning, and molecular dynamics simulation) to address some of society's most challenging healthcare issues. Our quest is to find new therapeutic candidates for autoimmune and inflammatory diseases such as lupus, psoriasis, rheumatoid arthritis, Alzheimer's, and diabetes. The mission is to develop breakthrough safe and effective therapies for unmet needs in autoimmune/inflammatory diseases.

Awards & Achievements

- ✓ Korea Health Industry Development Institute (\$0.1 million start-up) (2020.06.01)
- ✓ Selected as the excellent company in Kibo Venture Camp (2020.6.19)
- ✓ Minister's Award (Ministry of Science and ICT) (2020.12.02)
- ✓ Investment : Three VCs and TIPS (\$2.1 million) (May–August 2021).
- ✓ Certification of Venture and Enterprise Research Institute (2021.08)
- ✓ Biocore facility project selection (\$0.6 million) (2022.01)
- ✓ R&D service voucher support project (\$50 thousand) (2022.04)
- ✓ Tasks to support verification of bio data (\$60 thousand) (2022.05)

Organizational Structure

CEO

Management Support Division

- Administration Department
- Finance & Accounting Department
- Materials Management
- Partnership Cooperation
- Patent Management

R&D Planning Division

- R&D Planning Office

Research Institute

- Drug Discovery Department
- Artificial Intelligence
 - Target Discovery
 - Molecular Dynamics
 - Lead Optimization
- Experimental Department
- In Vitro Screening
 - In Vivo Testing
 - Mechanism Verification

Development Pipeline

Order	Targets	Target diseases	2022	2023	2024	2025	2026	2027
S&K101	TLR3/7/9	SLE/Psoriasis	nonGLP preclinical	GLP preclinical	Phase 1 clinical trial	Phase 2 clinical trial		
S&K201	NLRP3	Alzheimer's disease NASH	Candidate derivation	nonGLP preclinical	GLP preclinical	Phase 1 clinical trial		
S&K301	IL6R	RA/Crohn's disease	Candidate derivation	nonGLP preclinical	GLP preclinical	Phase 1 clinical trial		
S&K401	IL1 β	Nonalcoholic steatohepatitis	Candidate derivation					
S&K501	TNF α /IL18	Rheumatoid arthritis/Crohn's disease	Candidate derivation					

Future Expansion/Indications



Drug approval

- Systemic lupus erythematosus
- Alzheimer's disease
- Nonalcoholic steatohepatitis
- Rheumatoid arthritis



1st expansion of indications

- Psoriasis
- Type 2 diabetes
- Multiple sclerosis
- Gout
- Atherosclerosis
- Crohn's disease
- Insulin-dependent diabetes
- Steroid-resistant asthma



2nd expansion of indications

- Sjogren's syndrome
- Glomerulonephritis
- Autoimmune thyroiditis/hepatitis/anemia
- Sepsis
- Asthma
- Ankylosing spondylitis
- Respiratory diseases
- Optic neuritis
- Waldenstrom's macroglobulinemia
- Primary IgA nephropathy ...
- Various autoimmune/inflammatory diseases (over 100 types)